. Author manuscript; available in PMC: 2017 Feb 17.

Published in final edited form as: Cancer Chemother Pharmacol. 2014;73(6):1285–1293. doi: 10.1007/s00280-014-2466-0

Table 1.

Characteristics of the pharmacokinetic study population

Characteristics	Patients of the two phase I studies median [range]	Patients of CAPAGEC median [range]	P
Number of patients	40	20
Gender (Female/Male)	15/25	12/8	0.098
Age (years)	54.5 [30–73]	80.5 [75–92]	3. 10⁻¹⁰
Body weight (kg)	68 [41–95]	74 [48–113]	0.055
Body surface area (m²)	1.80 [1.40–2.10]	1.82 [1.41–2]	0.52
Total Bilirubin (μmol/L)	8.8 [3–22]	5.1 [2–13.3]	0.001
Cl_CR (ml/min)	71 [28–115]	66 [23–137]	0.13